96 related articles for article (PubMed ID: 2648580)
1. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Speth PA; Minderman H; Haanen C
Semin Oncol; 1989 Feb; 16(1 Suppl 2):2-9. PubMed ID: 2648580
[No Abstract] [Full Text] [Related]
2. A review of idarubicin in acute leukemia.
Berman E
Oncology (Williston Park); 1993 Oct; 7(10):91-8, 104; discussion 104-7. PubMed ID: 8251309
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients.
Robert J; Rigal-Huguet F; Huet S; Pris J; Hurteloup P
Leukemia; 1990 Mar; 4(3):227-9. PubMed ID: 2179640
[TBL] [Abstract][Full Text] [Related]
4. Comparative pharmacokinetic study of idarubicin and daunorubicin in leukemia patients.
Robert J; Rigal-Huguet F; Hurteloup P
Hematol Oncol; 1992; 10(2):111-6. PubMed ID: 1592361
[TBL] [Abstract][Full Text] [Related]
5. [New anthracyclines].
Ogawa M; Ariyoshi Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results in secondary acute non-lymphocytic leukemia (ANLL) treated with Idarubicin.
Parmentier C; Finaud M; Schlumberger M; Morardet N; Berger R; Bayle C; Carde P; Hurteloup P; Hayat M
Nouv Rev Fr Hematol (1978); 1985; 27(6):393-5. PubMed ID: 3867854
[TBL] [Abstract][Full Text] [Related]
7. Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA.
Petti MC; Mandelli F
Semin Oncol; 1989 Feb; 16(1 Suppl 2):10-5. PubMed ID: 2928805
[No Abstract] [Full Text] [Related]
8. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
Tidefelt U; Sundman-Engberg B; Paul C
Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin in acute leukemia: results of US trials.
Berman E; Raymond V; Gee TS; Kempin SJ; Gulati S; Andreeff M; Gabrilove J; Young CW; Clarkson BD; Wiernik PH
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():49. PubMed ID: 2713561
[No Abstract] [Full Text] [Related]
11. Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia.
Harousseau JL; Hurteloup P; Reiffers J; Rigal-Huguet F; Hayat M; Dufour P; Le Prise PY; Monconduit M; Jaubert J; Carcassonne Y
Cancer Treat Rep; 1987 Oct; 71(10):991-2. PubMed ID: 3477319
[No Abstract] [Full Text] [Related]
12. A phase II comparative study of idarubicin plus cytarabine versus daunorubicin plus cytarabine in adult acute myeloid leukemia.
Masaoka T; Ogawa M; Yamada K; Kimura K; Ohashi Y
Semin Hematol; 1996 Oct; 33(4 Suppl 3):12-7. PubMed ID: 8916311
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients.
Robert J; Rigal-Huguet F; Harousseau JL; Pris J; Huet S; Reiffers J; Hurteloup P; Tamassia V
Leuk Res; 1987; 11(11):961-4. PubMed ID: 3480399
[TBL] [Abstract][Full Text] [Related]
14. [Clinical pharmacology of idarubicin].
Robak T
Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
[TBL] [Abstract][Full Text] [Related]
15. Comparative chemotherapy of AKR lymphoma and human hematological neoplasia.
Frei E; Schabel FM; Goldin A
Cancer Res; 1974 Jan; 34(1):184-93. PubMed ID: 4520419
[No Abstract] [Full Text] [Related]
16. Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center.
Berman E; Raymond V; Gee T; Kempin SJ; Gulati S; Andreeff M; Kolitz J; Gabrilove J; Heller G; Young CW
Semin Oncol; 1989 Feb; 16(1 Suppl 2):30-4. PubMed ID: 2928808
[No Abstract] [Full Text] [Related]
17. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells.
Fukushima T; Ueda T; Uchida M; Nakamura T
Int J Hematol; 1993 Apr; 57(2):121-30. PubMed ID: 8494991
[TBL] [Abstract][Full Text] [Related]
18. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
19. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
[TBL] [Abstract][Full Text] [Related]
20. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]